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Introduction
Breast cancer is the most common cancer in women and 
a leading cause of cancer death worldwide. Management 
of breast cancer relies on the availability of robust clinical 
and pathological prognostic and predictive factors to 
guide patient decision making and the selection of 
treatment options. In early-stage breast cancer, where the 
use of systemic therapy has to be determined for every 
patient, the three main prognostic determinants used in 
routine practice are lymph node (LN) status, tumor size, 
and histological grade. Th e Nottingham (Elston-Ellis) 
modi fi  cation of the Scarff -Bloom-Richardson grading 
system, also known as the Nottingham Grading System 
(NGS) [1], is the grading system recommended by 
various professional bodies internationally (World Health 
Organi zation [WHO], American Joint Committee on 
Cancer [AJCC], European Union [EU], and the Royal 
College of Pathologists (UK RCPath) [2,3]).
Th e prognostic relevance of NGS in breast cancer was 
initially demonstrated in 1991 [1] and has been validated 
subsequently in multiple independent studies [4-14]. 
Since NGS has independent but equally powerful prog-
nostic value, it has been combined with LN stage and 
tumor size to form prognostic indices: the Nottingham 
Prognostic Index (NPI) [15], which includes NGS and LN 
stage with equal weighting, and the Kalmar Prognostic 
Index [4], in which grade is given a higher-weighted 
value. Owing to the prognostic information provided by 
NGS, it has also been incorporated in algorithms (for 
example, Adjuvant! Online [16]) and guidelines (for 
example, the St. Gallen guidelines [17]) to determine the 
use of adjuvant chemotherapy. NGS provides a simple, 
inexpensive, and routinely applicable overview of the 
intrinsic biological characteristics and clinical behavior 
of tumors, adding important informa tion to other 
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signi fi cant and at least partly time-dependent prognostic 
factors, such as tumor size and LN status.
Although the current well-established clinical and 
histological factors and some well-defi ned biological 
factors (that is, hormone receptors and HER2 expression) 
show strong association with prognosis and outcome, 
there are increasing concerns that these variables are 
limited in their ability to capture the diversity of clinical 
behaviors of breast cancer and that they would not be 
suffi  cient to tailor the therapy to individual patients. In 
addition, the perceived subjective nature of histo patho-
logical assessment of the morphological features such as 
tumor grade has increased these concerns. Th e intro-
duction of high-throughput technologies that survey 
thousands of genes and their products in a single assay, 
coupled with powerful analytical tools, has opened up 
new avenues for classifying breast cancer into biologically 
and clinically distinct groups based on gene expression 
patterns [18,19] and DNA copy number alterations [20]. 
However, these expression profi ling studies have 
suggested that molecular tests could perform better than 
the traditional histopathology and may replace it as the 
‘gold standard’ for prognostication and prediction of 
response to therapy [21]. Recent studies leading to the 
development of the 21-gene recurrence score (trade 
name Oncotype DX; Genomic Health, Inc., Redwood 
City, CA, USA [22,23]) have highlighted the issue of sub-
jec tivity associated with histological grading and called 
into question the utility of histological grade as a prog-
nostic tool. Regrettably, these results have been perceived 
as direct evidence that molecular tests provide an 
objective and reproducible assessment of prognostic 
features of estrogen receptor (ER)-positive breast cancers 
but that histopathological analyses are subjec tive and not 
reproducible.
Molecular methods undoubtedly provide prognostic 
and predictive information and may help identify new 
therapeutic targets, and the interest in molecular classi-
fi ers and their potential application is perfectly under-
standable. However, it is important to understand their 
limitations and critically evaluate their role in improving 
breast cancer prognostication above and beyond the 
traditional variables in a practical and cost-eff ective way 
[24,25]. Th e role of NGS as a simple and cost-eff ective 
method of assessment of tumor biology should not be 
neglected. It is also important to recognize that in 
countries with limited health resources, access to expen-
sive new technologies may not be possible but that 
eff ective cost-effi  cient methods, such as routine histo-
patho logical evaluation, are available for all [26]. In fact, 
there are numerous lines of evidence to suggest that these 
molecular tests complement rather than replace the 
traditional pathological variables, such as NGS, to defi ne 
the optimal therapy for patients with breast cancer.
Here, we present an overview of the current evidence 
of the signifi cance of breast cancer grading in view of the 
availability of an increasing number of potentially alter-
na tive molecular prognostic tests. We present in a prag-
matic way a comparison between NGS and recent 
molecular prognostic tests, taking into account evidence-
based clinical and biological signifi cance, cost-eff ective-
ness, practicality of application in diff erent parts of the 
world, and the impact of this on future plans for improve-
ment in breast cancer prognostication and management.
What is histological grade?
Invasive carcinomas are morphologically subdivided 
accord ing to their growth patterns and degree of 
diff erentiation, the latter of which refl ects how closely they 
resemble normal breast epithelial cells. Th is subdivision is 
achieved by assessing histological type and histological 
grade, respectively. Although tumor type provides useful 
prognostic information, the majority (60% to 75%) of 
breast cancers have no special type of characteristics (that 
is, invasive ductal carcinoma of no special type, or NST); 
those special types that show distinct prognostic signifi -
cance are relatively uncommon. As a consequence, the role 
of histological typing in clinical management decision 
making is currently limited [27].
Histological tumor grade is based on the degree of 
diff erentiation of the tumor tissue. In breast cancer, it 
refers to the semi-quantitative evaluation of morpho-
logical characteristics and is a relatively simple and low-
cost method, requiring only adequately prepared 
hematoxylin-eosin-stained tumor tissue sections to be 
assessed by an appropriately trained pathologist using a 
standard protocol. NGS is based on the evaluation of 
three morphological features: (a) degree of tubule or 
gland formation, (b) nuclear pleomorphism, and (c) mito-
tic count (Figure 1). For details, see [1,2] and Supple-
mentary Information [28].
Histological grade and prognosis
Multiple independent studies have shown that NGS has 
prognostic value that is equivalent to that of LN status [29] 
and greater than that of tumor size [4,15]. In a large study, 
Henson and colleagues [14], who assessed survival rates of 
22,616 cases of breast cancer, demonstrated that patients 
with histological grade 1, stage II disease had the same 
survival as those with grade 3, stage I disease. Th e authors 
also found that patients with grade 1 tumors of less than 2 
cm in size had an excellent prognosis, with 99% 5-year 
survival, even when they presented with positive LN. 
Th ese results are supported by a recent study from the 
Nottingham group [11], which included 2,219 operable 
breast cancer cases with long-term follow-up. Th is study 
has demonstrated that grade is an important determinant 
of breast cancer outcome and complemen tary to LN stage 
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through the ability to infl uence the outcome of patients 
in diff erent LN stage categories. Th ese results provide 
evidence that histological grade, when used in 
conjunction with LN stage, can improve the prediction of 
outcome for individual patients and support its inclusion 
and use in multifactorial indices such as the NPI and 
Adjuvant! Online. Similar long-term validation has been 
demonstrated in screen-detected breast cancer in the 
Swedish Two-County Trial, which demonstrated that 
tumor grade, LN status, and tumor size at the time of 
diagnosis have a lasting infl uence on subsequent 
survival [10].
Th ere is compelling evidence to suggest that histo logical 
grade can accurately predict tumor behavior, particularly 
in earlier small tumors (tumor, node, meta stasis [TNM] 
stage pT1), more than other ‘time-dependent’ prognostic 
factors such as tumor size (pT1a, pT1b, and pT1c) 
[4,9,11,15]. Studies have also demonstrated that grade is 
an independent prognostic factor in specifi c subgroups 
of breast cancer, including ER-positive breast cancer 
patients who have not [30] or who have received 
neoadjuvant endocrine therapy [31] and patients with 
LN-negative [5,11,13,32] or -positive [7,11] breast cancer 
regardless of ER expression. Recently, Desmedt and 
colleagues [33] demonstrated that in the ER-positive/
HER2-negative tumors (n = 628), only histological grade 
and the proliferation module retained their association 
with relapse-free survival (RFS) in the multivariate 
analysis (hazard ratio [HR] = 2.00, 95% confi dence 
interval [CI] 1.18 to 3.37; P = 0.01). In the Nottingham 
series [11,34], histological grade was an independent 
predictor of RFS in the ER-positive/HER2-negative 
tumors (n = 1,077) (HR = 2.13, 95% CI 1.79 to 2.53; 
P  <0.0001). Similar associations between grade and 
survival were found in (a) the LN-negative subgroup 
(n = 797), who received only adjuvant hormone therapy 
(HR = 1.85, 95% CI 1.46 to 2.34; P <0.0001, with rates of 
10-year risk of relapse of 7% for grade 1, 14% for grade 2, 
and 31% for grade 3), and in (b) ER-positive tumors with 
small-volume LN metastasis (pN1; one to three LNs 
positive) (n = 316) (HR = 2.07, 95% CI 1.51 to 2.86; 
P <0.0001, with rates of 10-year risk of relapse of 5% for 
grade 1, 24% for grade 2, and 43% for grade 3) [11,34]. 
Th erefore, histological grade can provide important 
prognostic information for clinically relevant subgroups 
in which the benefi t of chemotherapy is less certain (for 
example, LN-negative/ER-positive or in patients with 
low-volume LN metastatic disease).
We have noted, consistently with the biological and 
clinical roles of histological grade on breast cancer 
behavior, an important association between histological 
grade and pattern of survival. Akin to high-grade 
lymphoma, high-grade breast cancers tend to recur and 
metastasize early following diagnosis, typically within the 
fi rst 8 years; thereafter, breast cancer-related deaths 
decrease in frequency. Low-grade tumors tend to show a 
very good outcome, and few (if any) events occur; those 
that do occur, do so relatively late in the lifetime of the 
patients. Grade 2 tumors show an intermediate outcome 
during the early years of follow-up; however, on long-
term follow-up, they show an obvious trend for continued 
recurrence and impaired outcome in the long term 
[11,35] (Figure  2). In contrast, LN stage, which can 
provide information on the likelihood of death or survival 
after breast cancer, shows limited value in predicting the 
timescale of these events (Rakha EA, Ellis IO, 
unpublished data). Th is important observation provides 
further insight into the appropriate management strate-
gies of patients with breast cancer. High-grade tumors, 
with their risk of early recurrence and death, require 
consideration for prompt use of adjuvant chemotherapy, 
whereas patients with grade 1 tumors, which are almost 
Figure 1. Histological grade of breast cancer as assessed by the Nottingham Grading System. (a) A well-diff erentiated tumor (grade 1) that 
demonstrates high homology to the normal breast terminal duct lobular unit, tubule formation (>75%), a mild degree of nuclear pleomorphism, 
and low mitotic count. (b) A moderately diff erentiated tumor (grade 2). (c) A poorly diff erentiated (grade 3) tumor with a marked degree of cellular 
pleomorphism and frequent mitoses and no tubule formation (<10%).
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invariably ER-positive, could be off ered a long-term 
follow-up with or without a potentially less toxic systemic 
therapy (that is, endocrine therapy).
Histological grade: contentious issues
Despite the utility of histological grade as a prognostic 
factor for ER-positive disease, there are numerous issues 
that ought to be considered for the correct use of 
histological grade in the management of patients with 
breast cancer [36-39]. Th ese issues are detailed in the 
following sections.
Grade and size
Th e latest (7th edition) AJCC TNM staging system 
endorsed NGS, but grade was not included in calculating 
stage [40]. Th e decision to exclude grade as an element in 
the TNM staging system, as stated previously [36], is 
based mainly on the possible interaction between tumor 
size and histological grade and, in particular, the lack of 
clear evidence for the role of grade in small tumors (pT1 
and pT2). It should be noted that two of the basic 
principles of breast cancer screening are that outcome of 
patients with small invasive cancers is good and adverse 
events are rare. Th e eff ect of all known prognostic factors 
will therefore be limited in such a patient group. 
However, despite this constraint, there are several lines of 
evidence that demonstrate the prognostic signifi cance of 
NGS in small tumors. Studies that examine the prog-
nostic signifi cance of grade in small tumors quoted in the 
AJCC article by Singletary and colleagues [36] show 
marked variations in outcome, follow-up times, and 
number of patients. Th ere was also variation in the grad-
ing method used, and information on histological grade 
was obtained from systematic pathology review, whereas 
in others, information about grade was abstracted from 
pathology reports, medical records, or tumor registry 
databases. Th ese diff erences in grading systems and study 
design are expected to lead to diff erent results regarding 
the prognostic signifi cance not only of grade but also of 
other variables should they have been assessed. To 
conclude, although extracting consistent data on the 
prognostic signifi cance of grade from the diff erent studies 
cited in the AJCC review [36] is challenging, studies in 
which modern methods for histological grading were 
employed have shown that its utility is retained in small 
tumors [1,5,6,9,11,27,32,41-43]. With the shift that 
mammographic screening causes in stage distribution, 
this issue has become increasingly impor tant, with a high 
proportion of tumors being T1N0M0 at diagnosis, 
thereby limiting the relevance of TNM staging in routine 
practice.
In the Nottingham series, development of recurrent 
disease following diagnosis of grade 1 breast cancer was 
infrequent, and when observed, the recurrent lesions 
were either higher-grade tumors or second primaries. 
Th e number of patients with grade 1 tumors who 
developed distant metastasis or died without developing 
a second event of higher-grade tumor was limited (4%) 
[44]. Th is observation implies that grade 1 breast cancer 
studies that do not include pathology review and 
evaluation of the second event are likely to overestimate 
the risk of adverse outcome.
Further justifi cation for the exclusion of grade from 
TNM [36] is that large tumors (pT3 and pT4) tend to be 
Figure 2. Relationship between histological grade and breast 
cancer-specifi c survival. (a) In the old Nottingham series (1977 to 
1989), no systemic therapy was off ered to the patients. Of the 1,816 
patients, 404 (17.7%) had grade 1 tumors (gray curve), 621 (36.2%) 
had grade 2 (blue curve), and 791 (46.1%) had grade 3 (black curve) 
(χ2 = 97.5, P <0.0001). (b) In the recent Nottingham series (1990 to 
2002), systemic therapy was off ered to the patients according to 
Nottingham Prognostic Index and estrogen receptor expression 
as described previously [11]. Of the 3,579 patients, 677 (18.9%) had 
grade 1 tumors (gray curve), 1,383 (38.6%) had grade 2 (blue curve), 
and 1,519 (42.4%) had grade 3 (black curve) (χ2 = 195.5, P <0.0001). 
Analysis of grade 1 and 2 only showed statistical survival diff erence 
(χ2 = 20.7, P <0.0001). Both series are consecutive and included 
estrogen receptor-positive and -negative and lymph node-negative 
and -positive cases [11,75,76].
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high-grade and nearly always carry a recommendation 
for adjuvant chemotherapy, irrespectively of tumor grade. 
Although a higher proportion of larger tumors are 
grade 3 [8,11], some forms of lower-grade breast cancer 
such as hormone receptor-positive, low-grade invasive 
lobular cancers frequently present as large mammo-
graphi cally occult tumors and are responsive to hormone 
therapy. Furthermore, if tumor size/stage alone largely 
dictates an oncologist’s choice of treatment, an argument 
could be made, at least in many centers, for the 
irrelevance of other biological variables, including gene 
expression signatures such as Oncotype DX, 70-gene 
signature, 76-gene signature, and genomic grade index 
(GGI). Likewise, although NGS might have limited prog-
nostic value in HER2-positive and triple-negative cancers 
as most of these tumors are of high grade (grade 3) 
[30,33], these tumors also typically exhibit poor-prog-
nosis gene signatures [45]. In addition, molecular 
classifi ers such as Oncotype DX and GGI [33] and the 
MammaPrint (Agendia, Amsterdam, Th e Netherlands), 
the last of which is recommended to all patients, have 
negligible discriminatory power in ER-negative disease 
[30,33].
Th erefore, we believe that treatment decisions based on 
TNM staging system, which measures the anatomic 
extent of the tumor, can be improved by the addition of 
histological grade, which measures the intrinsic bio-
logical features of the tumor and refl ects the potential of 
a carcinoma to metastasize or cause death. Integration of 
histological grade into the relevant TNM staging system 
has been accepted for other common epithelial tumors 
such as adenocarcinoma of the prostate. As the prog-
nostic value of NGS has been proven in operable breast 
cancer (stages I and II), in which decisions about systemic 
therapy usage and its regimen need to be made, histo-
logical grade could be incorporated in the TNM system 
to improve its ability to stratify cases into risk-associated 
subcategories corresponding to grade so that chemo-
therapy can be potentially be avoided in low-risk groups 
and considered a high priority for patients in a high-risk 
category. Th e maximum benefi t of grade assessment 
would be in the subgroup of patients with ER-positive, 
LN stage N0 or N1 disease. Th e current evidence 
indicates that grading has limited value in advanced or 
metastatic breast cancer (stages III and VI) and grading is 
not expected to change treatment decisions and therefore 
need not be considered in these cases.
Grade and tumor type
Th e prognostic value of histological grade has been docu-
mented in most tumor types, including invasive lobular 
carcinomas [46]. Medullary carcinoma might appear to 
be one subtype in which grading is less signifi  cant. By 
defi nition, these tumors are of high histological grade 
(grade 3) but may have a more favorable prognosis than 
their histological grade would imply [38]. However, a 
recent study shows that medullary carcinomas account 
for less than 1% of breast cancers as a result of the strict 
criteria required for its recognition and that they do not 
have a prognosis signifi cantly diff erent than that of other 
forms of grade 3 ductal carcinoma with prominent 
infl am mation [38]. Importantly, a recent study suggested 
that the 70-gene prognostic signature may also fail to 
provide prognostic stratifi cation of patients with some 
special types of breast cancer. Given that NGS has been 
shown to provide prognostically relevant information for 
invasive ductal carcinomas of NST and lobular carci-
nomas, which together account for greater than 80% of 
all breast cancers, the systematic inclusion of histological 
type in breast cancer routine synoptic reports is also 
advo cated.
Grading of needle core biopsy specimens
Current evidence suggests that histological grading can 
be assessed relatively reliably whereas other well-estab-
lished prognostic factors, such as vascular invasion and 
tumor size, cannot [47,48]. However, some cases may be 
upgraded when the excision specimen is analyzed follow-
ing grading of core biopsies (that is, grade I in the core 
biopsy and grade II in the excision specimen; 30% to 40%). 
On the other hand, a diagnosis of NGS grade III in a core 
biopsy is not commonly changed when the excision 
specimen is graded (5% to 8%). Importantly, changes from 
grade I in the core to grade III in the excision specimen 
and vice versa are very rare (0% to 1%) [47,48].
Selection of patients for neoadjuvant therapy requires 
that prognostic information be available from non-
operative diagnostic tumor samples. Amat and colleagues 
[49] reported that assessment of grade on needle core 
biopsy (NCB) is a strong predictive factor of response to 
induction chemotherapy in breast cancer, independently 
of the type of regimen used. Th erefore, despite the 
limitations associated with the accuracy of grading core 
biopsies related to tumor sampling issues and visibility of 
mitotic fi gures [47,48], assessment of histological grade 
on NCB can provide information to support preoperative 
treatment decision making.
Reproducibility of histological grade
One of the reasons cited in the past for the reluctance to 
use grading in patient management decisions has been 
the perceived lack of reproducibility of the method. Th is 
may be highlighted by the relatively wide variation in the 
proportion of each grade in published series. However, a 
substantial number of studies have reported better levels 
of inter- and intra-observer concordance [1,27,50-59] 
(Table 1). Th e variation in the proportion of each grade 
reported in the diff erent studies can be explained by the 
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variation in the grading system used and the diff erence in 
the patient cohorts, including age distribution, 
symptomatic versus screening popula tion, early versus 
advanced breast cancer groups, and details of tissue 
fi xation. Grading is dependent on a high quality of tissue 
preservation. Suboptimal levels of tissue fi xation lead to 
disruption and loss of visibility of mitotic fi gures, one of 
the three variables assessed in NGS. Assessment of grade 
in poorly fi xed tissue will therefore introduce a bias 
leading to a reduction in the proportion of cases classifi ed 
as grade 3 [1,2,60].
Another important point to improve the inter-observer 
agreement rates is the introduction of guidelines for 
standardization of pre-analytical parameters, including 
tissue handling, fi xation, and preparation, and of the 
methods for tumor grading. Diff erences between centers 
can be attributed in many cases to diff erences in the 
quality of tissue preparation [2,61]. Critical evaluation of 
these issues and recommendations for good practice have 
been provided by professional organizations (that is, 
WHO, EU, UK RCPath, and the International Union 
Against Cancer [UICC]) [2]. Th e use of rigorously opti-
mized and standardized methods in Nottingham has 
provided a high NGS reproducibility between grading of 
a recent series [11] and that of an old series published 
more than two decades ago from the same institution 
with a similar percentage of cases in each grade (Table 2). 
Signifi cant improvements in the consistency of histo-
logical grading have been observed on a national basis in 
the UK through the publication of guidelines with linked 
educational activity and associated external quality 
assurance (EQA) [51]. Th ese guidelines provide not only 
information on histological grading methodology but 
also recommendations on the application of these 
methods and guidance on tissue handling. Adherence to 
these guidelines and participation in EQA are also 
expected to improve assessment of other important 
prognostic factors in breast cancer, such as lympho-
vascular invasion and immunohistochemical determina-
tion of other biomarkers. In addition, the current use of 
NGS is expected to provide consistency among diff erent 
studies in the future as evidenced from multiple studies 
from the Nottingham group and other institutions that 
endorse NGS [2,39,60,62]. However, despite the objective 
improvements that have been made to breast cancer 
grading methods, any assessment of morphological 
characteristics inevitably retains a subjective element and 
is heavily dependent on the pre-analytical parameters.
It should be noted that the degree of scrutiny of the 
inter-observer reproducibility histological grade has never 
been applied to molecular tests in current clinical use. A 
more detailed reproducibility study of the performance of 
gene expression studies has not been conducted as of yet. 
In fact, issues of reproducibility are well recognized in all 
forms of medical laboratory testing. Despite the 
undeniable need to improve the inter-observer agree ment 
for histological grade, the criticisms directed against NGS 
should be tempered by the fact that other parameters used 
to determine the therapy of patients with breast cancer 
also suff er from inter-observer variability, including the 
assessment of small-volume nodal metastases (LN stage), 
HER2 immunohisto chemical and in situ hybridization 
scoring, ER scoring, assessment of vascular invasion, and 
even the assessment of tumor size.
Signifi cance of grade 2 tumors
Mis-assignments of grade I to grade III or vice versa are 
rarely reported, but grade II tumors usually show the 
Table 1. Inter-observer and intra-observer agreement of breast cancer histological grade.
Study Number of cases Number of readers Grade Inter-observer
[32] 613 2 NGS Kappa 0.69
[8] 52 2 NGS Kappa 0.54
[55] 425 2 NGS Complete agreement 76%
[50] 75 6 NGS Kappa 0.43 to 0.74
[51] 12 600 NGS Kappa 0.45 to 0.53 (fi gures after application of guidelines)
[52]  3 NGS Complete agreement 72.3%; kappa 0.57
[53] 24 21 NGS Complete agreement 69%; kappa 0.53
[54] 50 5 NGS Mean polychoric correlation 0.8
[56] 35 13 NGS Kappa 0.5 to 0.7
[57] 93 7 NGS Kappa 0.54
[58] 40 3 NGS Kappa 0.68 to 0.83
[59] 874 2 WHO criteria Complete agreement 78.1%; kappa 0.66
[61] 50 5 NGS Complete agreement 83.3%; kappa 0.73
NGS, Nottingham Grading System; WHO, World Health Organization.
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lowest degree of concordance. Th is is an expected 
phenomenon of scoring of a biological variable where 
scores in the overlap regions are usually most diffi  cult to 
be categorised. Th e similar example of the problem of 
repro ducibility of classifi cation of a continuous biological 
variable was noted in the microarray-based gene expres-
sion profi ling studies [63,64]. For example, in the studies 
by Sorlie and colleagues [18] and Chang and colleagues 
[65], only a propor tion of cases could be accurately 
classifi ed into the molecular subtypes, 9% to 15% of 
tumors could not be assigned as grade 1 and grade 3 by 
GGI [66], and 19% to 24% of cases showed discordance 
among diff erent gene expression signatures applied to the 
same set of tumors [45].
In the latest meeting of the St. Gallen International 
Expert Consensus on the Primary Th erapy of Early Breast 
Cancer (2009) [17], it was recommended that grade 1 and 
grade 3 be taken into consideration for the assessment of 
indications of adjuvant chemotherapy. Grade 2 was 
regarded as being similar to other parameters of 
intermediate-risk signifi cance, such as tumor size of 
between 2 and 5 cm, low numbers (one to three) of 
involved LNs, and intermediate scores on multigene 
assays, and it was inferred that they do not provide a 
defi nitive indication of risk with respect to the clinical 
decision of whether to give or withhold chemo therapy. 
However, it was also noted that the presence of these 
intermediate-risk criteria usually tips the balance toward 
the use of chemotherapy [17].
Th e advantage of applications of molecular tests as 
complements to grade is particularly evident with respect 
to grade 2 tumors. Several attempts have been made to 
improve biological and clinical signifi cance of histological 
grading by classifying grade 2 tumors into two distinct 
subclasses: a grade 1-like subgroup, which has an 
excellent outcome and may not require adjuvant chemo-
therapy, and a grade 3-like subgroup, which comprises 
tumors that behave in a way similar to high-grade cancers 
and need a more aggressive systemic treatment. 
Examples of these studies include the application of GGI 
to subclassify histological grade 2 into two molecular 
subclasses (GGI1 and GGI3) [66] or the use of prolifera-
tion biomarkers such as MIB1 (Ki67) expression (Rakha 
EA, Ellis IO, unpublished data). However, the clinical 
useful ness and the cost-benefi t ratios of these studies 
need to be further evaluated if they are to be translated 
into routine practice worldwide, particularly in countries 
with limited resources.
Grade and molecular profi ling
Recent profi ling studies of breast cancer have emphasized 
the relevance of tumor biology in governing breast cancer 
behavior and hence the importance of histological grade. 
Tumors of diff erent histological grades show distinct 
molecular profi les at the genomic, transcriptomic, and 
immuno histochemical levels. Th ese results suggest that 
the majority of high-grade tumors are unlikely to stem 
from the progression of low-grade cancers and that grade 
1 and 3 breast tumors are probably diff erent diseases [67].
Gene expression studies have demonstrated that 
histological grade better refl ects the molecular makeup 
of breast cancer than LN status and tumor size do [68,69]. 
Sotiriou and colleagues [66] developed a 97-gene 
classifi er that can accurately identify cases diagnosed as 
NGS I or NGS III. Th eir studies have shown an asso cia-
tion between a ‘gene signature’ developed to recapitulate 
Table 2. Proportion of grades among diff erent studies.
Study Number of cases Grade 1 Grade 2 Grade 3
Elston, 1984 [77] 625 17% 37% 46%
Davis et al., 1986 [78] 1,537 22% 49% 29%
Hopton et al., 1989 [59] 874 29% 46% 25%
Le Doussal et al., 1989 [79] 1,262 11% 45% 46%
Balslev et al., 1994 [80] 9,149 32% 49% 19%
Saimura et al., 1999 [5] 741 19 37% 44%
Reed et al., 2000 [32] 613 25% 41% 35%
Simpson et al., 2000 [7] 368 22% 45% 33%
Lundin et al., 2001 [6] 1,554 26% 47% 27%
Frkovic-Grazio and Bracko, 2002 [9] 270 38% 38% 24%
Warwick et al., 2004 [10] 1,988 23% 37% 40%
Williams et al., 2006 [26] 1,058 20% 46% 34%
Rakha et al., 2008 [11] 2,219 18% 36% 46%
Thomas et al., 2009 [81] 1,650 26% 45% 29%
Blamey et al., 2009 [12] 16,944 29% 41% 30%
Rakha et al. Breast Cancer Research 2010, 12:207 
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histological grade (GGI) of breast cancer and patient 
outcome, indepen dently of LN status or tumor size [66]. 
Th is assay is currently being commercialized in Europe 
(MapQuant Dx; Ipsogen, Marseille, France). When the 
prognostic performance of GGI was compared with the 
Oncotype DX [22] and 70- and 76-gene signatures, a 
similar separation in distant metastasis-free survival 
between low- and high-risk groups by the three 
signatures was found [45]. Another group has similarly 
demonstrated that the genetic grade signature (RNA-
based) remained signifi cantly associated with disease 
recurrence in most cases.
However, recent meta-analyses of microarray-based 
expression profi ling studies have demonstrated that the 
prognostic impact of the signatures investigated stems 
from the proliferation-related genes [30,33]. In fact, when 
several of the published signatures were divided into 
partial signatures composed of proliferation-related genes 
and genes not related to proliferation, the latter failed to 
show prognostic signifi cance, whereas the prog nostic 
power of some signatures even improved by the removal of 
genes not related to proliferation [30]. Most importantly, 
in numerous studies using molecular signatures, 
histological grade remained an independent prognostic 
factor for ER-positive tumors even after the inclusion of 
gene signatures in the multivariate models [22,25].
Th ere are several lines of evidence to suggest that the 
objective contribution of gene signatures above and 
beyond the current clinicopathological parameters is 
limited. Dunkler and colleagues [70] demonstrated that 
the explained variation of prognosis (that is, the 
proportion of patients whose prognosis is determined 
solely by a given parameter) by prognostic signatures is 
limited (for example, 3% for the 70-gene signature) when 
grade and other clinicopathological variables such as LN 
stage, patient age, and ER status are included in the 
survival models [30,70,71]. It is important to mention, 
however, that there are relatively few head-to-head 
compari sons of NGS versus molecular signatures and 
that most of them so far have a competitive tone to them. 
Studies that combine molecular assays and NGS in a 
balanced manner would be warranted.
Grade in the era of molecular profi ling tests
Prognostic molecular tests for patients with breast 
cancer, including Oncotype DX [22] and MammaPrint 
[72], have already been approved for clinical use. 
Undoubtedly, these assays support breast cancer prog-
nos tication and can be used as a complement to the well-
established variables currently used in routine practice 
[73], as recently recommended in the St. Gallen guide-
lines [17].
Th e cost of MammaPrint and Oncotype DX [74] is 
orders of magnitude higher than that of histological 
grading. Oncotype DX has undergone health economic 
evaluation in the US and has been reported to be cost-
benefi cial through reduction of widespread use and 
appropriate targeting of use of adjuvant chemotherapy. In 
countries or centers where chemotherapy is less widely 
prescribed or where targeting is based on other tests, 
there may be a reduced benefi t and justifi cation of the 
test cost [26]. Th ere is a trend in the research community 
not to consider cost-eff ectiveness when promoting the 
use of a newly developed molecular test, even though 
costs typically are taken into consideration when 
evaluating new interventions [26,74]. Th e costs of these 
modern assays are likely to remain high, and it should be 
borne in mind that there are still many parts of the world 
that do not and will not have ready access to these costly 
tests. Th erefore, histological grading, when carried out 
properly on well-fi xed specimens, provides a simple, 
inexpensive, and highly accurate alternative method for 
assessing tumor biological characteristics and patient 
prognosis and identifying patients at high and low risk 
for adverse outcomes. In addition, the cost and availa-
bility are not the only factors limiting the routine 
applicability of currently approved or recommended 
molecular prognostic assays as there may also be some 
skepticism of the scientifi c rigor of industry-sponsored 
cost-benefi t economic models.
Given that grade has been shown by multiple indepen-
dent groups to be prognostic and that the levels of inter-
observer agreement have increased with the adoption of 
NGS, it is rather surprising that clinical practice has 
changed with molecular tests that have not been as 
comprehensively tested but has not changed with NGS. 
Possibly, this stems from the purported objectivity of 
molecular tests and the denounced subjectivity of 
histopathological analysis [25]. However, molecular tests 
also suff er from subjectivity in terms of the biostatistical 
approaches employed, the stability of the molecular 
subgroups identi fi ed by the tests, and the reproducibility 
of assays performed with cell extracts without careful 
micro dissection of tumor cells (that is, contamination 
with normal breast epithelial cells or proliferating stromal 
cells may change the results of molecular tests based on 
the assessment of ER- and proliferation-related genes) 
[25]. Th erefore, it should be recognized that both 
molecular assays and NGS have their own strengths and 
weak nesses, which vary in diff erent situations. Both can 
provide valuable prognostic information and both should 
complement rather than compete with each other and 
this should be understood when they are used for patient 
management decision making. When used in combi na-
tion, molecular tests such as GGI are potentially impor-
tant in the subclassifi cation of grade 2 breast tumors. 
However, the application of molecular tests to known 
grade 1 and grade 3 breast cancers in the treatment 
Rakha et al. Breast Cancer Research 2010, 12:207 
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decision-making process may need further validation and 
confi rmation of any additional prognostic value and cost 
benefi t.
Conclusions
Th ere is an international consensus that NGS should be 
considered the ‘gold standard’ for breast cancer grading. 
Th e adoption of the objective criteria of NGS has been 
shown to overcome many of the previous problems of 
reproducibility of grading, problems that resulted from 
using a variety of approaches. To provide a consistent 
and uniform way of assessing histological grade and to 
improve its reproducibility, consensus criteria and 
guidelines have been published with critical evaluation of 
these issues and recommendations for good practice [2]. 
Strict adherence to these criteria is expected to improve 
consistency and reproducibility of breast cancer grading 
among diff erent institutions. Histological grading, when 
adequately carried out, provides a simple, inexpensive, 
and highly accurate method for assessing tumor bio-
logical characteristics and patient prognosis. Th is is of 
particular importance for breast cancer patients in parts 
of the world where access to new molecular technology is 
not currently available. Molecular assays and NGS should 
complement rather than compete with each other. We 
conclude that the assessment of histological grade is an 
important determinant of breast cancer prognostication 
and should be incorporated in staging systems and in 
algorithms to defi ne therapy for patients with breast 
cancer.
Take-home messages
Th e Nottingham Grading System, when adequately 
carried out, provides a simple, inexpensive, accurate, and 
validated method for assessing patient prognosis.
Consensus criteria for histological grading and recom-
mendations for good practice have been published [2,51] 
and should be followed.
Th e Nottingham Grading System is a validated 
alternative to molecular tests in parts of the world where 
access to new molecular technology is not currently 
available or likely to become available in the near future.
Assessment of histological grade is an important 
determinant of breast cancer prognostication and should 
be incorporated in algorithms to defi ne therapy for 
patients with breast cancer.
Search strategy and selection criteria
Literature databases, including PubMed, Medline, and 
the Cochrane Library, were searched for articles 
published from 1980 to 2009 in English. Th e keywords 
used for the search were ‘breast cancer’, ‘grade’, ‘histo-
logic(al) grade’, ‘molecular profi le’, and ‘reproducibility’ in 
relation to biology, prognosis, prediction, and patient 
outcome. Articles published before 1980 or in another 
language were also considered if they were commonly 
referenced or were highly regarded older publications. 
Th e search also included the references list for these 
articles and selected additional articles and webpages 
that were judged to be relevant. Data from publications 
submitted as abstracts were excluded.
Abbreviations
AJCC, American Joint Committee on Cancer; CI, confi dence interval; EQA, 
external quality assurance; ER, estrogen receptor; EU, European Union; GGI, 
genomic grade index; HR, hazard ratio; LN, lymph node; NCB, needle core 
biopsy; NGS, Nottingham Grading System; NPI, Nottingham Prognostic Index; 
NST, no special type; RFS, relapse-free survival; TNM, tumor, node, metastasis; 
UK RCPath, Royal College of Pathologists; WHO, World Health Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EAR and JSR-F performed the literature review and helped write the fi rst 
draft of the manuscript. SB and IOE helped write the fi rst draft. All authors 
contributed to the writing and approval of the fi nal and revised drafts of the 
manuscript.
Acknowledgments
On 16 October 2008, the Susan G Komen for the Cure sponsored a meeting 
of pathologists to review and make recommendations regarding the utility of 
histological grade in breast cancer staging and prognostication. This report 
was conceived in that meeting. JSR-F is funded in part by Breakthrough Breast 
Cancer. The funding sources had no role in the literature search or in the 
drafting and approval of the manuscript.
Author details
1Department of Histopathology, Nottingham University Hospitals NHS Trust, 
Nottingham City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, 
UK; 2The Breakthrough Breast Cancer Research Centre, Institute of Cancer 
Research, Fulham Road, London, SW3 6JB, UK; 3Department of Anatomic 
Pathology, University of California, Divisadero Street, Box 1785, San Francisco, 
CA 94143, USA; 4University of Pittsburgh Medical Center, Halket Street, 
Pittsburgh, PA 15213, USA; 5Breast-Screening-Pathology, Reference Centre 
Münster, Gerhard Domagk-Institute of Pathology, University Hospital Münster, 
Domagkstrasse 17, D-48149 Münster, Germany; 6Sezione Anatomia Istologia e 
Citologia Patologica ‘M. Malpighi’, Università-ASL Ospedale Bellaria, Via Altura 3, 
40139 Bologna, Italia; 7Pathology Department, Peter MacCallum Cancer Centre, 
St Andrews Place, East Melbourne, Victoria 3002, Australia; 8Department 
of Pathology, Nagoya Medical Center 4-1-1 Sannomaru, Naka ku, Nagoya 
460 0001, Japan; 9Unité d’Anatomie et de Cytologie Pathologiques, Institut 
Paoli-Calmettes, 13273 Marseille, Cedex 9, France; 10Molecular and Cellular 
Pathology, The University of Queensland, Mayne Medical School, Brisbane, 
QLD 4006, Australia; 11Servicio de Anatomía Patológica, Hospital Universitario 
Virgen del Rocío, Avda. Manuel Siurot, s/n, 41013 Sevilla, Spain; 12Department 
of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, 
MA 02115, USA; 13Department of Pathology, Beth Israel Deaconess Medical 
Center and Harvard Medical School, 330 Brookline Avenue, #Sl435, Boston, MA 
02215, USA; 14Institute of Molecular Pathology and Immunology (IPATIMUP) 
and Medical Faculty, University of Porto, R. Roberto Frias, S/N, 4200 - Porto, 
Portugal; 15Department of Pathology, Singapore General Hospital, Outram 
Road, Singapore 169608; 16Department of Anatomical and Cellular Pathology, 
Prince of Wales Hospital, Ngan shing Street, Shatin, Hong Kong; 17Departments 
of Pathology and Internal Medicine, Clarian Pathology Lab of Indiana 
University, 350 West 11th Street, CPL-4050, Indianapolis, IN 46202, USA.
Published: 24 August 2010
References
1. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer I. The 
value of histological grade in breast cancer: experience from a large study 
with long-term follow-up. Histopathology 1991, 19:403-410.
2. Pathology Reporting of Breast Disease: A Joint Document Incorporating the Third 
Rakha et al. Breast Cancer Research 2010, 12:207 
http://breast-cancer-research.com/content/12/4/207
Page 9 of 12
Edition of the NHS Breast Screening Programme’s Guidelines for Pathology 
Reporting in Breast Cancer Screening and the Second Edition of The Royal 
College of Pathologists’ Minimum Dataset for Breast Cancer Histopathology. 
Sheffi  eld; NHS Cancer Screening Programmes and The Royal College of 
Pathologists; January 2005.
3. Tavassoli FA, Devilee P: World Health Organization classifi cation of tumours. 
In Pathology and Genetics Tumours of the Breast and Female Genital Organs. 
Lyon: IARC Press; 2003:19-23.
4. Sundquist M, Thorstenson S, Brudin L, Nordenskjold B: Applying the 
Nottingham Prognostic Index to a Swedish breast cancer population. 
South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 
1999, 53:1-8.
5. Saimura M, Fukutomi T, Tsuda H, Sato H, Miyamoto K, Akashi-Tanaka S, 
Nanasawa T: Prognosis of a series of 763 consecutive node-negative 
invasive breast cancer patients without adjuvant therapy: analysis of 
clinicopathological prognostic factor. J Surg Oncol 1999, 71:101-105.
6. Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkanen L, Turpeenniemi-
Hujanen T, Joensuu H: Omission of histologic grading from clinical decision 
making may result in overuse of adjuvant therapies in breast cancer: 
results from a nationwide study. J Clin Oncol 2001, 19:28-36.
7. Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, 
Page DL, Robert NJ: Prognostic value of histologic grade and proliferative 
activity in axillary node-positive breast cancer: results from the Eastern 
Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 
2000, 18:2059-2069.
8. Anderson TJ, Alexander FE, Lamb J, Smith A, Forrest AP: Pathology 
characteristics that optimize outcome prediction of a breast screening 
trial. Br J Cancer 2000, 83:487-492.
9. Frkovic-Grazio S, Bracko M: Long term prognostic value of Nottingham 
histological grade and its components in early (pT1N0M0) breast 
carcinoma. J Clin Pathol 2002, 55:88-92.
10. Warwick J, Tabar L, Vitak B, Duff y SW: Time-dependent eff ects on survival in 
breast carcinoma: results of 20 years of follow-up from the Swedish 
Two-County Study. Cancer 2004, 100:1331-1336.
11. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, 
Ellis IO: Prognostic signifi cance of nottingham histologic grade in invasive 
breast carcinoma. J Clin Oncol 2008, 26:3153-3158.
12. Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L, 
Fourquet A, Gee J, Holli K, Jakesz R, Kerin M, Mansel R, Nicholson R, 
Pienkowski T, Pinder S, Sundquist M, van de Vijver M, Ellis I: ONCOPOOL - 
A European database for 16,944 cases of breast cancer. Eur J Cancer 2010, 
46:56-71.
13. Mirza AN, Mirza NQ, Vlastos G, Singletary SE: Prognostic factors in node-
negative breast cancer: a review of studies with sample size more than 
200 and follow-up more than 5 years. Ann Surg 2002, 235:10-26.
14. Henson DE, Ries L, Freedman LS, Carriaga M: Relationship among outcome, 
stage of disease, and histologic grade for 22,616 cases of breast cancer. 
The basis for a prognostic index. Cancer 1991, 68:2142-2149.
15. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index 
in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
16. Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, 
Armstrong N, van’t Veer LJ, Ravdin PM: Calibration and discriminatory 
accuracy of prognosis calculation for breast cancer with the online 
Adjuvant! program: a hospital-based retrospective cohort study. Lancet 
Oncol 2009, 10:1070-1076.
17. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ: 
Thresholds for therapies: highlights of the St Gallen International Expert 
Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 
2009, 20:1319-1329.
18. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, 
Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-
Dale AL, Botstein D: Repeated observation of breast tumor subtypes in 
independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 
100:8418-8423.
19. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, 
Harris AL, Liu ET: Breast cancer classifi cation and prognosis based on gene 
expression profi les from a population-based study. Proc Natl Acad Sci U S A 
2003, 100:10393-10398.
20. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, 
Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, 
Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, 
Waldman FM, Gray JW: Genomic and transcriptional aberrations linked to 
breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541.
21. Peppercorn J, Perou CM, Carey LA: Molecular subtypes in breast cancer 
evaluation and management: divide and conquer. Cancer Invest 2008, 
26:1-10.
22. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, 
Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: 
A multigene assay to predict recurrence of tamoxifen-treated, node-
negative breast cancer. N Engl J Med 2004, 351:2817-2826.
23. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, 
Bryant J, Costantino JP, Geyer CE Jr., Wickerham DL, Wolmark N: Gene 
expression and benefi t of chemotherapy in women with node-negative, 
estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
24. Correa Geyer F, Reis-Filho JS: Microarray-based gene expression profi ling as 
a clinical tool for breast cancer management: are we there yet? Int J Surg 
Pathol 2009, 17:285-302.
25. Weigelt B, Baehner FL, Reis-Filho JS: The contribution of gene expression 
profi ling to breast cancer classifi cation, prognostication and prediction: 
a retrospective of the last decade. J Pathol 2010, 220:263-280.
26. Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, 
Gray A, Harris A, Johnston K, Lodge M: Cost-eff ectiveness of using 
prognostic information to select women with breast cancer for adjuvant 
systemic therapy. Health Technol Assess 2006, 10:iii-iv, ix-xi, 1-204.
27. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, 
Robertson JF, Ellis IO: Pathological prognostic factors in breast cancer. 
IV: Should you be a typer or a grader? A comparative study of two 
histological prognostic features in operable breast carcinoma. 
Histopathology 1995, 27:219-226.
28. Assessment of breast cancer grading using the Nottingham combined 
histological grading system [http://www.nottingham.ac.uk/~mrzarg/nott.
htm].
29. Walker RA: Prognostic and Predictive Factors in Breast Cancer. 1st edition. New 
York: Informa Health Care; 2003.
30. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, 
Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, 
Delorenzi M: Meta-analysis of gene expression profi les in breast cancer: 
toward a unifi ed understanding of breast cancer subtyping and prognosis 
signatures. Breast Cancer Res 2008, 10:R65.
31. Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von 
Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M: Outcome prediction 
for estrogen receptor-positive breast cancer based on postneoadjuvant 
endocrine therapy tumor characteristics. J Natl Cancer Inst 2008, 
100:1380-1388.
32. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J: The 
prognostic value of p53 and c-erb B-2 immunostaining is overrated for 
patients with lymph node negative breast carcinoma: a multivariate 
analysis of prognostic factors in 613 patients with a follow-up of 
14-30 years. Cancer 2000, 88:804-813.
33. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, 
Delorenzi M, Piccart M, Sotiriou C: Biological processes associated with 
breast cancer clinical outcome depend on the molecular subtypes. Clin 
Cancer Res 2008, 14:5158-5165.
34. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee 
AH, Robertson JF, Ellis IO: Biologic and clinical characteristics of breast 
cancer with single hormone receptor positive phenotype. J Clin Oncol 
2007, 25:4772-4778.
35. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, 
Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO: Invasive lobular 
carcinoma of the breast: Response to hormonal therapy and outcomes. 
Eur J Cancer 2008, 44:73-83.
36. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark 
G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, 
Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Revision of the 
American Joint Committee on Cancer staging system for breast cancer. 
J Clin Oncol 2002, 20:3628-3636.
37. Pedersen L, Zedeler K, Holck S, Schiodt T, Mouridsen HT: Medullary 
carcinoma of the breast. Prevalence and prognostic importance of 
classical risk factors in breast cancer. Eur J Cancer 1995, 31A:2289-2295.
38. Rakha EA, El-Sayed ME, Reed J, Lee AH, Evans AJ, Ellis IO: Screen-detected 
breast lesions with malignant needle core biopsy diagnoses and no 
malignancy identifi ed in subsequent surgical excision specimens 
Rakha et al. Breast Cancer Research 2010, 12:207 
http://breast-cancer-research.com/content/12/4/207
Page 10 of 12
(potential false-positive diagnosis). Eur J Cancer 2009, 45:1162-1167.
39. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, 
O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ: 
Prognostic factors in breast cancer. College of American Pathologists 
Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:966-978.
40. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer 
Staging Manual. 7th edition. New York: Springer; 2010.
41. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN: Prognosis and 
management of patients with node-negative invasive breast carcinoma 
that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the 
literature. J Clin Oncol 2006, 24:2113-2122.
42. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP: 
Predictive factors associated with axillary lymph node metastases in T1a 
and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll 
Surg 2000, 191:1-6; discussion 6-8.
43. Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JF, Blamey RW: The 
prognosis of small primary breast cancers. Eur J Cancer 1999, 35:908-912.
44. Rakha EA, Lee AH, Evans AJ, Menon S, Assad NY, Hodi Z, Macmillan D, Blamey 
RW, Ellis IO: Tubular carcinoma of the breast: further evidence to support 
its excellent prognosis. J Clin Oncol 2010, 28:99-104.
45. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van‘t Veer LJ, Perou 
CM: Concordance among gene-expression-based predictors for breast 
cancer. N Engl J Med 2006, 355:560-569.
46. Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO: Histologic 
grading is an independent prognostic factor in invasive lobular carcinoma 
of the breast. Breast Cancer Res Treat 2008, 111:121-127.
47. Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO: Preoperative assessment of 
prognostic factors in breast cancer. J Clin Pathol 2001, 54:20-24.
48. Rakha EA, Ellis IO: An overview of assessment of prognostic and predictive 
factors in breast cancer needle core biopsy specimens. J Clin Pathol 2007, 
60:1300-1306.
49. Amat S, Penault-Llorca F, Cure H, Le Bouedec G, Achard JL, Van Praagh I, Feillel 
V, Mouret-Reynier MA, Dauplat J, Chollet P: Scarff -Bloom-Richardson (SBR) 
grading: a pleiotropic marker of chemosensitivity in invasive ductal breast 
carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002, 
20:791-796.
50. Frierson HF Jr., Wolber RA, Berean KW, Franquemont DW, Gaff ey MJ, Boyd JC, 
Wilbur DC: Interobserver reproducibility of the Nottingham modifi cation 
of the Bloom and Richardson histologic grading scheme for infi ltrating 
ductal carcinoma. Am J Clin Pathol 1995, 103:195-198.
51. Ellis IO, Coleman D, Wells C, Kodikara S, Paish EM, Moss S, Al-Sam S, Anderson 
N, Bobrow L, Buley I, Connolly CE, Dallimore NS, Hales S, Hanby A, Humphreys 
S, Knox F, Lowe J, Macartney J, Nash R, Parham D, Patnick J, Pinder SE, Quinn 
CM, Robertson AJ, Shrimankar J, Walker RA, Winder R: Impact of a national 
external quality assessment scheme for breast pathology in the UK. J Clin 
Pathol 2006, 59:138-145.
52. Theissig F, Kunze KD, Haroske G, Meyer W: Histological grading of breast 
cancer. Interobserver, reproducibility and prognostic signifi cance. Pathol 
Res Pract 1990, 186:732-736.
53. Jacquemier J, Charpin C: [Reproducibility of histoprognostic grades of 
invasive breast cancer]. Ann Pathol 1998, 18:385-390.
54. Chowdhury N, Pai MR, Lobo FD, Kini H, Varghese R: Interobserver variation in 
breast cancer grading: a statistical modeling approach. Anal Quant Cytol 
Histol 2006, 28:213-218.
55. Page DL, Gray R, Allred DC, Dressler LG, Hatfi eld AK, Martino S, Robert NJ, 
Wood WC: Prediction of node-negative breast cancer outcome by 
histologic grading and S-phase analysis by fl ow cytometry: an Eastern 
Cooperative Oncology Group Study (2192). Am J Clin Oncol 2001, 24:10-18.
56. Longacre TA, Ennis M, Quenneville LA, Bane AL, Bleiweiss IJ, Carter BA, 
Catelano E, Hendrickson MR, Hibshoosh H, Layfi eld LJ, Memeo L, Wu H, 
O’malley FP: Interobserver agreement and reproducibility in classifi cation 
of invasive breast carcinoma: an NCI breast cancer family registry study. 
Mod Pathol 2006, 19:195-207.
57. Boiesen P, Bendahl PO, Anagnostaki L, Domanski H, Holm E, Idvall I, 
Johansson S, Ljungberg O, Ringberg A, Ostberg G, Fernö M: Histologic 
grading in breast cancer--reproducibility between seven pathologic 
departments. South Sweden Breast Cancer Group. Acta Oncol 2000, 
39:41-45.
58. Sikka M, Agarwal S, Bhatia A: Interobserver agreement of the Nottingham 
histologic grading scheme for infi ltrating duct carcinoma breast. Indian J 
Cancer 1999, 36:149-153.
59. Hopton DS, Thorogood J, Clayden AD, MacKinnon D: Observer variation in 
histological grading of breast cancer. Eur J Surg Oncol 1989, 15:21-23.
60. European Commission: European Guidelines for Quality Assurance in 
Mammography Screening. Luxembourg: Offi  ce for Offi  cial Publications of the 
European Communities; 1996.
61. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C: 
Histological grading of breast carcinomas: a study of interobserver 
agreement. Hum Pathol 1995, 26:873-879.
62. Pathology and genetics of tumors of the breast and female genital organs. 
In World Health Organization Classifi cation of Tumors. Edited by Tavassoli FA, 
Devilee P. Lyon: IACR Press; 2003.
63. Lusa L, McShane LM, Reid JF, De Cecco L, Ambrogi F, Biganzoli E, Gariboldi M, 
Pierotti MA: Challenges in projecting clustering results across gene 
expression-profi ling datasets. J Natl Cancer Inst 2007, 99:1715-1723.
64. Nuyten DS, Chang HY, Brown PO, Van de Vijver MJ: Reproducibility of 
molecular portraits in early stage breast cancer. Breast Cancer Research 
2005, 7 (Suppl 2):P4.
65. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He 
YD, van’t Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ: 
Robustness, scalability, and integration of a wound-response gene 
expression signature in predicting breast cancer survival. Proc Natl Acad Sci 
U S A 2005, 102:3738-3743.
66. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, 
Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten 
D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M: Gene 
expression profi ling in breast cancer: understanding the molecular basis 
of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 
98:262-272.
67. Natrajan R, Lambros MB, Geyer FC, Marchio C, Tan DS, Vatcheva R, Shiu KK, 
Hungermann D, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Buerger H, 
Reis-Filho JS: Loss of 16q in high grade breast cancer is associated with 
estrogen receptor status: Evidence for progression in tumors with a 
luminal phenotype? Genes Chromosomes Cancer 2009, 48:351-365.
68. Yu K, Lee CH, Tan PH, Hong GS, Wee SB, Wong CY, Tan P: A molecular 
signature of the Nottingham prognostic index in breast cancer. Cancer Res 
2004, 64:2962-2968.
69. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL: Predicting features 
of breast cancer with gene expression patterns. Breast Cancer Res Treat 
2008, 108:191-201.
70. Dunkler D, Michiels S, Schemper M: Gene expression profi ling: does it add 
predictive accuracy to clinical characteristics in cancer prognosis? Eur J 
Cancer 2007, 43:745-751.
71. Eden P, Ritz C, Rose C, Ferno M, Peterson C: ‘Good Old’ clinical markers have 
similar power in breast cancer prognosis as microarray gene expression 
profi lers. Eur J Cancer 2004, 40:1837-1841.
72. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, 
Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, 
Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, 
Bernards R: A gene-expression signature as a predictor of survival in breast 
cancer. N Engl J Med 2002, 347:1999-2009.
73. Bueno-de-Mesquita JM, Sonke GS, van de Vijver MJ, Linn SC: Additional 
value and potential use of the 70-gene prognosis signature in node-
negative breast cancer in daily clinical practice. Ann Oncol 2009 Dec 2. 
[Epub ahead of print].
74. Hornberger J, Cosler LE, Lyman GH: Economic analysis of targeting 
chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, 
estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 
2005, 11:313-324.
75. Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, Haybittle JL: 
Reading the prognosis of the individual with breast cancer. Eur J Cancer 
2007, 43:1545-1547.
76. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan 
D, Blamey RW, Ellis IO: High-throughput protein expression analysis using 
tissue microarray technology of a large well-characterised series identifi es 
biologically distinct classes of breast cancer confi rming recent cDNA 
expression analyses. Int J Cancer 2005, 116:340-350.
77. Elston CW: The assessment of histological diff erentiation in breast cancer. 
Aust N Z J Surg 1984, 54:11-15.
78. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, 
Golouh R, Süe-Söderbergh J, Holloway L, Russell I, Rudenstam CM: 
Prognostic signifi cance of tumor grade in clinical trials of adjuvant 
Rakha et al. Breast Cancer Research 2010, 12:207 
http://breast-cancer-research.com/content/12/4/207
Page 11 of 12
therapy for breast cancer with axillary lymph node metastasis. Cancer 
1986, 58:2662-2670.
79. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M: 
Prognostic value of histologic grade nuclear components of Scarff -Bloom-
Richardson (SBR). An improved score modifi cation based on a multivariate 
analysis of 1262 invasive ductal breast carcinomas. Cancer 1989, 
64:1914-1921.
80. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT: 
The Nottingham Prognostic Index applied to 9,149 patients from the 
studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast 
Cancer Res Treat 1994, 32:281-290.
81. Thomas JS, Kerr GR, Jack WJ, Campbell F, McKay L, Pedersen HC, Kunkler IH, 
Cameron DA, Chetty U, Bartlett JM: Histological grading of invasive breast 
carcinoma--a simplifi cation of existing methods in a large conservation 
series with long-term follow-up. Histopathology 2009, 55:724-731.
doi:10.1186/bcr2607
Cite this article as: Rakha EA, et al.: Breast cancer prognostic classifi cation 
in the molecular era: the role of histological grade. Breast Cancer Research 
2010, 12:207.
Rakha et al. Breast Cancer Research 2010, 12:207 
http://breast-cancer-research.com/content/12/4/207
Page 12 of 12
